Trial Profile
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 13 Jun 2019 Status changed from recruiting to completed.
- 09 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2017.
- 19 Oct 2015 New trial record